We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-24.42%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$137M
AUM Growth
+$14.4M
Cap. Flow
+$30.3M
Cap. Flow %
22.19%
Top 10 Hldgs %
90.6%
Holding
116
New
26
Increased
16
Reduced
32
Closed
31

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$13.7M
2
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$13.2M
3
EZGO
EZGO Technologies
EZGO
+$4.47M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$2.67M
5
DUO
Fangdd Network Group
DUO
+$2.19M

Top Sells

Rank Stock Value
1
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$1.71M
2
SONN
Sonnet BioTherapeutics
SONN
+$1.61M
3
SIDU icon
Sidus Space
SIDU
+$1.16M
4
ITRM
Iterum Therapeutics
ITRM
+$1.13M
5
AKTX
Akari Therapeutics
AKTX
+$741K

Sector Composition

Rank Sector Weight
1 Miscellaneous 88.59%
2 Healthcare 7.31%
3 Consumer Discretionary 1.12%
4 Communication Services 0.83%
5 Energy 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBLT
26
DELISTED
ToughBuilt Industries, Inc. Common Stock
TBLT
$297K 0.22%
+23,405
New +$436K
BETS
27
DELISTED
Bit Brother Limited Class A Ordinary Shares
BETS
$291K 0.21%
567
-344
-38% -$196K
REVB icon
28
Revelation Biosciences
REVB
$3.63M
$278K 0.2%
70
+9
+15% +$39.7K
ALLR
29
Allarity Therapeutics
ALLR
$17.7M
$268K 0.2%
+599
New +$768K
NEPT
30
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$247K 0.18%
186,890
+146,500
+363% +$799K
PHIO icon
31
Phio Pharmaceuticals
PHIO
$11.8M
$236K 0.17%
17,338
-79
-0.5% -$1.64K
VRPX
32
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$234K 0.17%
1,171
-429
-27% -$94.5K
HCDI
33
DELISTED
Harbor Custom Development, Inc. Common Stock
HCDI
$232K 0.17%
164,516
+10,373
+7% +$21K
GMDA
34
PUT
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$231K 0.17%
2,244
– –
BTBT icon
35
PUT
Bit Digital
BTBT
$527M
$223K 0.16%
1,044
+884
+553% +$2.77K
RVPH
36
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$218K 0.16%
+2,230
New +$208K
SCNI
37
Scinai Immunotherapeutics
SCNI
$1.04M
$213K 0.16%
2,450
+541
+28% +$69.3K
PMCB icon
38
PharmaCyte Biotech
PMCB
$4.1M
$204K 0.15%
+97,124
New +$248K
MRAI
39
DELISTED
Marpai, Inc. Class A Common Stock
MRAI
$198K 0.14%
299,077
-76,891
-20% -$96.7K
IVF
40
INVO Fertility Inc
IVF
$2.39M
$183K 0.13%
+160
New +$505K
GEVO icon
41
CALL
Gevo
GEVO
$388M
$142K 0.1%
1,197
+772
+182% +$1.14K
NCPL icon
42
Netcapital
NCPL
$3.4M
$137K 0.1%
4,772
-675
-12% -$31.6K
ENSC icon
43
Ensysce Biosciences
ENSC
$8.79M
$134K 0.1%
6,465
-15,022
-70% -$426K
RNAZ icon
44
TransCode Therapeutics
RNAZ
$1.69M
$126K 0.09%
7
+2
+40% +$126K
BGXX
45
DELISTED
Bright Green Corporation Common Stock
BGXX
$120K 0.09%
+304,183
New +$189K
GMDA
46
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$115K 0.08%
111,264
+52,322
+89% +$66.9K
RKDA icon
47
Arcadia Biosciences
RKDA
$1.04M
$110K 0.08%
32,705
-85,508
-72% -$350K
SXTPW icon
48
60 Degrees Pharmaceuticals Warrant
SXTPW
$51.7K
$107K 0.08%
+306,717
New +$132K
AMPGW
49
DELISTED
Amplitech Group Warrants
AMPGW
$102K 0.07%
415,869
-8,309
-2% -$2.87K
MOBQ
50
DELISTED
Mobiquity Technologies, Inc. Common Stock
MOBQ
$96.9K 0.07%
144,000
-485
-0.3% -$548
1
2
3 4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2023 Portfolio in Review

As of Q3 2023, Sabby Management held 116 positions worth $137M, up 12% from $122M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Sabby Management deployed $30.3M of net new capital in Q3 2023, opening 26 new positions and adding to 16 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 73,000 shares worth $12.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 77% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was BRAINSTORM CELL THERAPUTC, an estimated $1.71M trimmed.

  • Sabby Management's largest Q3 2023 buy was iShares Russell 2000 ETF: 73,000 shares worth $12.9M.
  • Sabby Management added most to Neptune Wellness Solutions Inc. Ordinary Shares in Q3 2023, an estimated $799K increase.
  • Sabby Management's biggest Q3 2023 reduction was BRAINSTORM CELL THERAPUTC, cutting an estimated $1.71M.
  • Sabby Management fully exited Sonnet BioTherapeutics in Q3 2023, selling an estimated $1.61M.
  • Sabby Management's ten largest holdings make up 91% of its $137M portfolio in Q3 2023.
  • Sabby Management opened 26 new positions and closed 31 in Q3 2023.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $137M.

Based on Sabby Management's 13F filing for Q3 2023, filed 14 Nov 2023.